BR112014013723A2 - formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico - Google Patents

formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico

Info

Publication number
BR112014013723A2
BR112014013723A2 BR112014013723A BR112014013723A BR112014013723A2 BR 112014013723 A2 BR112014013723 A2 BR 112014013723A2 BR 112014013723 A BR112014013723 A BR 112014013723A BR 112014013723 A BR112014013723 A BR 112014013723A BR 112014013723 A2 BR112014013723 A2 BR 112014013723A2
Authority
BR
Brazil
Prior art keywords
amino
pyrimidin
carbamoyl
phenyl
ethyl
Prior art date
Application number
BR112014013723A
Other languages
English (en)
Other versions
BR112014013723A8 (pt
Inventor
Baumgartner Bruno
Billen Guenter
Mohnicke Mandy
Bröckelmann Martin
Nagel Norbert
Ritzeler Olaf
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112014013723A8 publication Critical patent/BR112014013723A8/pt
Publication of BR112014013723A2 publication Critical patent/BR112014013723A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico". a presente invenção refere-se a polimorfos e hidratos da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico, a processos para sua preparação e seu uso, em particular em composições farmacêuticas.
BR112014013723A 2011-12-06 2012-12-04 formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico BR112014013723A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306618 2011-12-06
PCT/EP2012/074339 WO2013083553A1 (en) 2011-12-06 2012-12-04 Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide

Publications (2)

Publication Number Publication Date
BR112014013723A8 BR112014013723A8 (pt) 2017-06-13
BR112014013723A2 true BR112014013723A2 (pt) 2017-06-13

Family

ID=47278314

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013723A BR112014013723A2 (pt) 2011-12-06 2012-12-04 formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico

Country Status (24)

Country Link
US (1) US9067918B2 (pt)
EP (1) EP2787998B1 (pt)
JP (1) JP6078551B2 (pt)
KR (1) KR20140103968A (pt)
CN (1) CN104105483B (pt)
AR (1) AR089078A1 (pt)
AU (1) AU2012347393B2 (pt)
BR (1) BR112014013723A2 (pt)
CA (1) CA2856607C (pt)
CY (1) CY1118615T1 (pt)
DK (1) DK2787998T3 (pt)
ES (1) ES2612217T3 (pt)
HR (1) HRP20170092T1 (pt)
HU (1) HUE031525T2 (pt)
IL (1) IL232693B (pt)
LT (1) LT2787998T (pt)
MX (1) MX351994B (pt)
PL (1) PL2787998T3 (pt)
PT (1) PT2787998T (pt)
RU (1) RU2631320C2 (pt)
SG (1) SG11201402461RA (pt)
SI (1) SI2787998T1 (pt)
UY (1) UY34497A (pt)
WO (1) WO2013083553A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
ES2697806T3 (es) * 2014-07-03 2019-01-28 Sanofi Sa [(S)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida del ácido 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-carboxílico para uso en el tratamiento de dolor asociado a artrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) * 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
WO2006076318A1 (en) * 2005-01-12 2006-07-20 Aventis Pharmaceuticals Inc. Monopotassium salt of an ikb kinase inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
WO2010102968A1 (en) * 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
PE20131326A1 (es) 2010-08-12 2013-11-12 Sanofi Sa Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico
PE20131351A1 (es) * 2010-09-30 2013-12-04 Boehringer Ingelheim Int Formas en estado solido de un potente inhibidor del vch

Also Published As

Publication number Publication date
CA2856607C (en) 2020-03-10
AR089078A1 (es) 2014-07-30
MX2014006838A (es) 2014-11-25
PL2787998T3 (pl) 2017-04-28
RU2014127478A (ru) 2016-02-10
EP2787998B1 (en) 2016-11-09
MX351994B (es) 2017-11-06
CY1118615T1 (el) 2017-07-12
KR20140103968A (ko) 2014-08-27
AU2012347393B2 (en) 2017-06-08
US20140336211A1 (en) 2014-11-13
SI2787998T1 (sl) 2017-02-28
CN104105483A (zh) 2014-10-15
SG11201402461RA (en) 2014-08-28
EP2787998A1 (en) 2014-10-15
DK2787998T3 (en) 2017-02-06
WO2013083553A1 (en) 2013-06-13
HRP20170092T1 (hr) 2017-03-24
ES2612217T3 (es) 2017-05-12
PT2787998T (pt) 2017-01-03
AU2012347393A1 (en) 2014-06-19
CA2856607A1 (en) 2013-06-13
CN104105483B (zh) 2017-03-22
HUE031525T2 (en) 2017-07-28
JP6078551B2 (ja) 2017-02-08
RU2631320C2 (ru) 2017-09-21
LT2787998T (lt) 2017-02-10
BR112014013723A8 (pt) 2017-06-13
IL232693B (en) 2018-07-31
US9067918B2 (en) 2015-06-30
IL232693A0 (en) 2014-07-31
JP2015500255A (ja) 2015-01-05
UY34497A (es) 2013-07-31

Similar Documents

Publication Publication Date Title
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112014011594A2 (pt) anticorpos anti-il-36r
IL233200A0 (en) The history of alpha-boronic acid, its preparation and pharmaceutical preparations containing it
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112013020352A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EP2344198A4 (en) LIPID (S) PHARMACEUTICAL PREPARATIONS FOR ORAL AND TOPICAL USE, COMPOSITIONS THEREOF, METHODS AND USES
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
PL2731947T3 (pl) Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
GT201300084A (es) Conjugado de naloxol-peg cristalino
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
IL227404A0 (en) Pyrimidine history, their preparation and pharmaceutical preparations containing them
EP2697238A4 (en) SOLID FORMS OF ANTIRETROVIRUS COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITION
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]